, June 10, 2014
/PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced it received the Healthcare Distribution Management Association's (HDMA's) 2014 Distribution Industry Award for Notable Achievement (DIANA) Award for the Best Manufacturer of the Year under $300 million
. Honoring pharmaceuticals and consumer product manufacturer members that set the standard of excellence in new product introductions and product promotions as well as build strong business practices with HDMA distributor members, the DIANA award has been the industry's most recognized symbol of excellence since 1959.
"We are very proud to receive this important recognition by such an esteemed organization," stated Mike Sullivan, President of Avion Pharmaceuticals. "This notoriety at such an early stage in our company's history is quite an achievement, and it speaks to our commitment to the pharmaceutical industry and our allegiance to our distributor partners."
Avion CEO Mark Pugh added, "Avion has been very focused and tenacious in striving for industry excellence over the past two years. We are proud that the HDMA is a strong partner and grateful for their recognition of our diligent efforts to succeed."
HDMA is the national association representing primary healthcare distributors the vital link between the nation's pharmaceutical manufacturers and healthcare providers. HDMA member companies ensure that 15 million prescription medicines and healthcare products are delivered each day to nearly 200,000 pharmacies, hospitals, long-term care facilities, clinics and other locations nationwide. The organization and its members generate an estimated average cost savings of $42 billion annually to the healthcare system in the U.S.
About Avion Pharmaceuticals, LLC.
Avion Pharmaceuticals, LLC., is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative products in the Women's Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.
SOURCE Avion Pharmaceuticals